Ignet

Gene Information

Gene symbol: PSG5

Gene name: pregnancy specific beta-1-glycoprotein 5

HGNC ID: 9522

Synonyms: FL-NCA-3, PSG

Related Genes

#	Gene Symbol	Number of hits
1	AFP	1 hits
2	ALPP	1 hits
3	CGB	1 hits
4	CGB5	1 hits
5	CSH1	1 hits
6	IGF1	1 hits
7	INS	1 hits
8	PRL	1 hits
9	PSG1	1 hits

Related Sentences

#	PMID	Sentence
1	422088	[Pregnancy-specific beta-1-glycoprotein (SP-1) during the second half of pregnancy].
2	422088	By evaluation of maternal serum concentrations of SP-1 in cases of high-risk pregnancies with EPH-gestosis and fetal retardation relevant results could be demonstrated.
3	1280539	Amniotic fluid (AF) and maternal serum (MS) chorionic gonadotropin (HCG), placental lactogen (HPL), pregnancy-specific beta 1-glycoprotein (SP1), total estrogens (ET), alpha-fetoprotein (AFP) and prolactin (PRL) were measured by enzyme-immunoassays, in 50 normal (A) and in 37 abnormal (B) pregnancies, from 16th to 40th weeks.
4	1280539	A: the proteins HCG, AFP and PRL showed a similar decreasing trend after the 20th week, while HPL and SP1 rose progressively throughout the 2nd trimester, thereafter remaining constant.
5	1280539	Chorionic gonadotropin HPL and SP1 in MS were higher than in AF, while AF values of AFP and PRL were higher than in MS, but the ratio MS/AF of all hormone values increased significantly from the 2nd to the 3rd trimester (p < 0.005-p < 0.000001).
6	1280539	In erythroblastosis and diabetes, AFP was very low, but placental hormones, PRL and ET were both high and low.
7	1280539	In toxemia, SP1, hCG and PRL were elevated, while HPL and ET were very low.
8	2481301	We correlated the villous histology with the immunocytochemical distribution of four trophoblastic proteins: beta human chorionic gonadotropin (beta HCG), placental alkaline phosphatase (PLAP), pregnancy specific beta-1-glycoprotein (SP1), and human placental lactogen (HPL) in 14 third-trimester placentas associated with diabetes mellitus.
9	2481301	Staining was increased for beta HCG and decreased for PLAP, SP1, and HPL in the diabetic placentas compared to control placentas of similar gestational age.
10	2783318	Serum concentrations of hCG, pregnancy-specific beta-1-glycoprotein, placental lactogen, and hCG alpha were measured serially.
11	6378262	Levels of human placental lactogen (HPL) were significantly elevated in B-noRx patients compared to PC and A and were lowered to levels comparable to normal in insulin-treated B patients.
12	6378262	Elevations of pregnancy-specific beta 1 glycoprotein were observed in patients with mild carbohydrate intolerance (A) as well as Bno-Rx, but were comparable to normal in those B-patients receiving insulin therapy.
13	6416936	Serum levels of pregnancy-specific beta 1-glycoprotein (SP1) in women with pregnancies at risk.
14	6416936	Pregnancy-specific beta 1-glycoprotein (SP1) concentrations were measured by nephelometry in 133 serum samples from 74 women in their last trimester of pregnancy.
15	6416936	Women with insulin-dependent diabetes mellitus who gave birth to infants to normal birth weight or large-for-date infants had SP1 levels well within the reference range and even showed a tendency to overrepresentation above the geometric mean.
16	6416936	Serum levels of pregnancy-specific beta 1-glycoprotein (SP1) in women with pregnancies at risk.
17	6416936	Pregnancy-specific beta 1-glycoprotein (SP1) concentrations were measured by nephelometry in 133 serum samples from 74 women in their last trimester of pregnancy.
18	6416936	Women with insulin-dependent diabetes mellitus who gave birth to infants to normal birth weight or large-for-date infants had SP1 levels well within the reference range and even showed a tendency to overrepresentation above the geometric mean.
19	6787188	Sp1, the pregnancy-specific beta 1-glycoprotein, was studied in normal and pathologic pregnancies.
20	6787188	Since the radioimmunological determination of SP1 is possible in the early stage of gestation (from week 8) it may serve as a useful tool for prediction at times when the determination of placental lactogen is not yet possible.
21	6787188	Serial determinations of SP1 in the serum of women with EPH-gestosis were compared with the corresponding HPL determinations and showed the equality of SP1 concerning the assessment of the placental function.
22	21672515	To realize the secretory expression of human insulin-like growth factor-I (hIGF-I) in the posterior silk glands (PSGs) of transgenic silkworms, the piggyBac transposon vector pigA3GFP-fibHS-hIGF-i.e.
23	21672515	-neo containing a neomycin-resistance gene (neo), green fluorescent protein gene (gfp) and human insulin-like growth factor I (hIGF-I) gene controlled by the Bombyxmori fibroin heavy chain gene (fib-H) promoter with its downstream signal peptide sequence, and a helper plasmid containing the piggyBac transposase sequence under the control of the B. mori actin 3 gene (A3) promoter were transferred into silkworm eggs by sperm-mediated gene transfer.
24	21672515	In the PSGs of the transformed silkworms, a specific band representing hIGF-I could be detected by Western blotting, and the content of the hIGF-I estimated by ELISA was approximately 1.84 μg/gram of cocoon and 19.18 μg/gram of freeze-dried PSG powder.
25	21672515	To further estimate the biological activity of the expressed hIGF-I, streptozotocin-induced TIDM mice were orally administered with the PSG powder of the transgenic silkworms, the results showed the blood glucose levels of mice were significantly reduced, suggesting that the the PSGs powder of transgenic hIGF-I silkworms could possibly be used as a perorally administered medicine.
26	21672515	To realize the secretory expression of human insulin-like growth factor-I (hIGF-I) in the posterior silk glands (PSGs) of transgenic silkworms, the piggyBac transposon vector pigA3GFP-fibHS-hIGF-i.e.
27	21672515	-neo containing a neomycin-resistance gene (neo), green fluorescent protein gene (gfp) and human insulin-like growth factor I (hIGF-I) gene controlled by the Bombyxmori fibroin heavy chain gene (fib-H) promoter with its downstream signal peptide sequence, and a helper plasmid containing the piggyBac transposase sequence under the control of the B. mori actin 3 gene (A3) promoter were transferred into silkworm eggs by sperm-mediated gene transfer.
28	21672515	In the PSGs of the transformed silkworms, a specific band representing hIGF-I could be detected by Western blotting, and the content of the hIGF-I estimated by ELISA was approximately 1.84 μg/gram of cocoon and 19.18 μg/gram of freeze-dried PSG powder.
29	21672515	To further estimate the biological activity of the expressed hIGF-I, streptozotocin-induced TIDM mice were orally administered with the PSG powder of the transgenic silkworms, the results showed the blood glucose levels of mice were significantly reduced, suggesting that the the PSGs powder of transgenic hIGF-I silkworms could possibly be used as a perorally administered medicine.
30	21672515	To realize the secretory expression of human insulin-like growth factor-I (hIGF-I) in the posterior silk glands (PSGs) of transgenic silkworms, the piggyBac transposon vector pigA3GFP-fibHS-hIGF-i.e.
31	21672515	-neo containing a neomycin-resistance gene (neo), green fluorescent protein gene (gfp) and human insulin-like growth factor I (hIGF-I) gene controlled by the Bombyxmori fibroin heavy chain gene (fib-H) promoter with its downstream signal peptide sequence, and a helper plasmid containing the piggyBac transposase sequence under the control of the B. mori actin 3 gene (A3) promoter were transferred into silkworm eggs by sperm-mediated gene transfer.
32	21672515	In the PSGs of the transformed silkworms, a specific band representing hIGF-I could be detected by Western blotting, and the content of the hIGF-I estimated by ELISA was approximately 1.84 μg/gram of cocoon and 19.18 μg/gram of freeze-dried PSG powder.
33	21672515	To further estimate the biological activity of the expressed hIGF-I, streptozotocin-induced TIDM mice were orally administered with the PSG powder of the transgenic silkworms, the results showed the blood glucose levels of mice were significantly reduced, suggesting that the the PSGs powder of transgenic hIGF-I silkworms could possibly be used as a perorally administered medicine.